BANK VONTOBEL/CALL/ELI LILLY & CO/400/0.1/21.06.24 | Delayed Deutsche Boerse AG 04:34:22 2024-06-05 EDT | ||
| 40.18 EUR | +1.06% |
|
| Current month | +3.73% | ||
| 1 month | +24.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-06-05 | 40.18 | +1.06% |
| 24-06-04 | 39.76 | +0.25% |
| 24-06-03 | 39.66 | +3.47% |
| 24-05-31 | 38.33 | -1.59% |
| 24-05-30 | 38.95 | +1.64% |
Delayed Quote Deutsche Boerse AG
Last update June 05, 2024 at 04:34 am
More quotesStatic data
| Product type | Warrant Plain-Vanilla |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VU6BRT |
| ISIN | DE000VU6BRT7 |
| Date issued | 2023-04-17 |
| Strike | 400 $ |
| Maturity | 2024-06-21 (17 Days) |
| Parity | 10 : 1 |
| Emission price | 3.94 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 40.21 € |
|---|---|
| Lowest since issue | 3.77 € |
| Spread | 0.21 € |
| Spread % | 0.52% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
832.6
USD
Average target price
852.5
USD
Spread / Average Target
+2.39%
- Stock Market
- Warrants
- Warrant
